Market News & Trends
N4 Pharma Provides Covid-19 Project & Operational Update
N4 Pharma Plc, the specialist pharmaceutical company developing Nuvec, a novel delivery system for cancer treatments and vaccines, recently announced it will be undertaking a…
Fast New Tests for Covid-19 on the Way
At present, polymerise chain reaction (PCR) and antibody testing are the dominant ways that global healthcare systems are testing citizens for Covid-19. Both techniques have…
NeuBase Therapeutics Announces Positive Preclinical Data
NeuBase Therapeutics, Inc. recently announced positive preclinical data from its pharmacokinetics studies in non-human primates (NHPs) and in vitro pharmacodynamics data in patient-derived cell lines.…
Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance Into Formal IND-Enabling Studies From Boehringer Ingelheim Collaboration
Oxford BioTherapeutics Ltd. recently announced that Boehringer Ingelheim has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled…
New Incentives & Benefits Can Boost R&D Ecosystem for New Drug Development in India
India has recently sought feedback from the top pharmaceutical companies to make regulatory changes that offer specific tax benefits for specialized research. With the government’s…
Malvern Panalytical & Concept Life Sciences Form Unique Partnership
Malvern Panalytical and Concept Life Sciences recently launched a new partnership that combines advanced instrumentation with expert analytical services for discovery and development. This collaboration…
Aravive Announces AVB-500 Improves Anti-Tumor Effects When Combined With Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib
Aravive, Inc. recently announced that AVB-500 improves anti-tumor effects when combined with the anti-angiogenic bevacizumab or the PARP inhibitor olaparib in preclinical uterine cancer models.…
Carterra Selected by La Jolla Institute of Immunology to Provide Antibody Screening & Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)
Carterra Inc. and La Jolla Institute for Immunology (LJI), announced today that they will use Carterra’s proprietary LSA platform to screen hundreds of antibodies in…
Saama Makes State-of-the-Art Clinical Analytics Platform Available to Integrate Data From All Organizations Investigating COVID-19 Treatments
Saama Technologies, Inc. recently announced it will contribute its AI-powered Life Science Analytics Cloud (LSAC) technology platform to establish the EndPandemic National Data Consortium…..
Horizon Discovery & Pharmahungary Report Positive Early Stage Results for Novel Micro-RNA Therapeutic
Horizon Discovery Group plc and Pharmahungary Group recently announced positive early stage results for a novel micro-RNA therapeutic for…………..
Altimmune & the University of Alabama Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
Altimmune, Inc. recently announced it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose…..
Proveris Scientific Announces 25th Anniversary; Reviews Key Milestones
Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, recently announced its 25th Anniversary and…
Covid-19 Outbreak in China Threatens Biopharma In-House Manufacturing
With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry’s supply….
Lonza Launches New TheraPEAK SfAAV Medium to Boost & Optimize the Production of AAV in Sf9 Insect Cells
Lonza recently announced the launch of the TheraPEAK SfAAV Medium, the first chemically defined, non-animal origin medium designed specifically for the production of….
Derm-Biome Pharmaceuticals Reports Positive Results From a Preclinical Study
Derm-Biome Pharmaceuticals, Inc. recently announced that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of….
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate From Premas Biotech
Akers Biosciences, Inc. recently announced it has acquired a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by…..
WPD Pharmaceuticals Partners With CNS Pharmaceuticals on Drug Development for Coronavirus & Other Antiviral Indications
WPD Pharmaceuticals Inc. recently announced it has entered into a development agreement with CNS Pharmaceuticals, Inc. for the development of……
Novavax’s NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Novavax, Inc. recently announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its…
SPI Pharma Expands Product Portfolio to Support Development, Manufacture & Administration of Oral Dosage Forms
SPI Pharma recently announced an expansion of its line of Mannogem Mannitol products for use in multiple patient-friendly oral dosage forms to now include: Mannogem…
Positive Update on the Development of New XF‐Platform Drug Formulations
Destiny Pharma recently announced the completion of the initial phase of its project with MedPharm to develop new topical formulations of the company’s novel XF‐platform…